Bellicum Pharmacueticals Inc. (NASDAQ:BLCM)’s share price traded down 4.6% during mid-day trading on Thursday . The company traded as low as $15.55 and last traded at $15.62, with a volume of 194,223 shares trading hands. The stock had previously closed at $16.38.

A number of equities analysts have recently issued reports on the stock. Piper Jaffray Cos. reiterated a “buy” rating on shares of Bellicum Pharmacueticals in a report on Saturday, July 9th. Zacks Investment Research upgraded shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a report on Monday, July 11th. Finally, SunTrust Banks Inc. initiated coverage on shares of Bellicum Pharmacueticals in a report on Thursday, June 2nd. They set a “buy” rating and a $20.00 target price for the company. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $27.50.

The firm’s 50-day moving average is $13.47 and its 200-day moving average is $11.21. The firm’s market capitalization is $425.00 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.07. Analysts anticipate that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current fiscal year.

In other news, CTO Kevin M. Slawin sold 2,719 shares of the business’s stock in a transaction on Monday, July 18th. The shares were sold at an average price of $13.99, for a total transaction of $38,038.81. Following the completion of the transaction, the chief technology officer now owns 134,206 shares of the company’s stock, valued at $1,877,541.94. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Ken Moseley sold 15,000 shares of the business’s stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total transaction of $195,000.00. Following the transaction, the vice president now directly owns 15,196 shares of the company’s stock, valued at approximately $197,548. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley boosted its stake in shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent reporting period.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.